ALLIANCE-A032102
Phase II
OPEN TO ACCRUAL
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
HARPOON-HPN328-4001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)
NRG-GU013
Phase III
OPEN TO ACCRUAL
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer